NATCOPHARM Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹647 Cr
verified against source
Revenue YoY
8.3%
reported change
EBITDA
₹216.8 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Natco Pharma delivered solid Q3 FY26 results with consolidated revenue of ₹705.4 crore (+8.3% YoY) and EBITDA of ₹216.8 crore (30.7% margin), demonstrating resilience amid zero Revlimid sales this quarter. The standout development is the DCGI approval expected shortly for generic Ozempic (semaglutide), with 350-400 MRs deployed for the India launch. Management guided FY26 revenue of ₹4,200-4,300 crore and PAT of ₹1,280-1,300 crore, projecting 20%+ domestic growth driven by semaglutide. The Adcock Ingram stake (35.75%) will contribute ₹35-40 crore quarterly going forward after one-time amortization. CEO flagged two-three large M&A targets in pipeline, with intent to close at least one in 2026. Emerging markets (Brazil, Canada, Middle East) drove export formulation growth of ₹135 crore YoY without Revlimid. Crop health demerger targeted within 8 months. The bullish thesis rests on rich ANDA pipeline launches (US FY27), strong Atco consolidation, and Geniesis CRISPR-Cas9 xenotransplantation investment (2-3 year multi-bagger potential if 25-30 patients demonstrate success). Key risks include intense semaglutide pricing competition in India and execution uncertainty on the pending acquisition target.
Colored figures show movement against the previous available record.
Guidance to track
- Management guided full-year FY26 consolidated revenue of ₹4,200-4,300 crore, based on 9M revenue of ₹3,559 crore and expected Q4 revenue of ₹700-750 crore.
- With 9M PAT at ₹1,150 crore, management expects full-year PAT of ₹1,280-1,300 crore, implying Q4 PAT guidance of ₹130-150 crore.
- NATCO's domestic business (₹450-460 crore annualized) targets 20%+ growth driven primarily by semaglutide launch, with MR force deployed and DCGI approval imminent.
- CEO Raju Panini indicated 2-3 M&A targets actively under pursuit, with target to close at least one large transaction (similar size to ₹3,700 crore Atco acquisition) in calendar year 2026.
Risks flagged
- CEO acknowledged semaglutide launch will face intense competition with multiple generic entrants, own-brand launches, out-licensing deals, and Margo's lower-priced variant already gaining traction in India.
- Chennai formulation plant inspection completed in 2025 with observations described as 'procedural in nature'; classification expected in 30-40 days could impact US formulation export capabilities.
- When pressed on acquisition timeline and specifics, CEO deflected saying 'until it's done, it's not done' without committing to deal size, geography, or vertical, creating execution uncertainty for the ₹2,500 crore cash deployment.
- With Revlimid completely absent this quarter (and Q4 not budgeted), the base quarterly revenue of ₹700-750 crore leaves limited margin for error before new product launches contribute in FY27.
Key quotes
- We're actively pursuing two three targets and we're hoping we'll able to close. Something large we want to close at least one in 2026 we want to close in this calendar year for sure.
- My expectation is that they're going to be a lot of generics. Each guy you know we're launching our own brand plus also be giving to two other people. So again all the other guys also I think they're launching their own brand. It'll be like a crowded generic market.
- Without M&A you will not get there. Organically, you'll get to a certain point but you need to do M&A for sure. And do I have such a number in mind? Of course, we have this number in mind. I'm totally aware of it.
Research modules